Fig 1: The structures of T-mfIL12 and T-mIL12-IRES.The boxes (top line) represent inverted repeat sequences flanking the long (UL) and short (US) unique sequences of HSV-1 DNA. Oncolytic HSV-1 uses G47∆ as the backbone and contains 1.0 kb deletions in both copies of the γ34.5 gene, a 0.3 kb deletion in the α47 gene, and a 0.9 kb deletion in the ICP6 gene. The lacZ gene and the cytomegalovirus (CMV) promoter-driven interleukin-12 (IL-12) gene are oriented in opposite directions, and inserted into the deleted ICP6 locus. T-mfIL12 contains a cassette carrying the p35 and p40 genes of murine IL-12 linked by two bovine elastin motifs. Murine IL-12 is expressed as a single fusion peptide and folds to become active. T-mIL12-IRES contains a cassette in which the p40 and p35 genes of murine IL-12 are separated by an internal ribosome entry site (IRES) sequence from the encephalomyocarditis virus (EMCV). The p40 and p35 subunits are efficiently co-expressed to form active murine IL-12. T-01 contains a cassette with no transgene.
Fig 2: Calhm6 −/− macrophages have a normal type I IFN response to Poly(I:C) injection A Splenocytes obtained from WT and Calhm6 −/− mice after 3 h Poly(I:C) (200 μg/mouse) or PBS injection were incubated for an additional 1 h with PMA/Ionomycin and then with Brefeldin A for an additional 3 h. Cells were stained for intracellular IFN‐γ and analysed by flow cytometry (results from one experiment, Poly(I:C) WT mice = 5, Calhm6 −/− mice = 5, control WT mice = 2, Calhm6 −/− mice = 2).B–I Experimental scheme: WT and Calhm6 −/− mice were injected with Poly(I:C) (200 μg/mouse) or PBS i.p. Spleens were collected 3 h and 6 h later and F4/80+ cells isolated with magnetic beads selection to collect RNA. Serum was collected from the injected mice 1 h or 3 h after Poly(I:C) (200 μg/mouse) injection and cytokines measured using LegendPlex kit. Gene expression of Ifna4 (C), Ifnb1 (D), Ifna14 (E), Il1r2 (F), Il12a (G), Il12b (H) and Calhm6 (I) was assessed by qPCR (WT mice = 5 and 5, Calhm6 −/− mice = 5 and 5, control mice = 1 and 1). Differences in these genes (expect Calhm6 itself) between WT and Calhm6 −/− were not statistically significant (results from one experiment, Poly(I:C) WT mice = 5, Calhm6 −/− mice = 5, control WT mice = 1, Calhm6 −/− mice = 1).J Membrane IL‐15ra expression on BMDCs after overnight LPS (100 ng/ml) or Poly(I:C) (50 μg/ml) treatment was measured by flow cytometry. MFI levels were normalised to WT set to 1 to allow pooling of independent experiments (pooled results from two independent experiments, WT mice = 6, Calhm6 −/− mice = 6).K–R Indicated serum cytokine levels from poly(I:C) injected mice were measured using Macrophage LegendPlex kit, except IFNβ which was measured using ELISA (pooled results from two independent experiments, Poly(I:C) WT mice = 8, Calhm6 −/− mice = 8–10, control mice = 4–5). Differences in these serum cytokines between WT and Calhm6 −/− were not statistically significant. Data information: *P < 0.05, ****P < 0.0001. Test = one‐way ANOVA with multiple comparisons, error bars represent SD.
Fig 3: Roles of Gq-GPCR-signaling in the effects on DCs. (A) mRNA levels of cytokine genes in LPS-stimulated DCs. 1.0 x 106/mL of BMDCs were stimulated by 100 ng/mL LPS for 4 h in the presence or absence of 50 μM enon FAs. (B, C) The amount of TNF-α, IL-6, and IL-12p40 released from LPS-stimulated DCs in the presence of the indicated concentrations of γKetoC or a Gq agonist (B) and those with a Gq inhibitor (C). BMDCs pretreated in the presence or absence of the indicated concentrations of γKetoC, GW9508, and/or YM-254890 for 24 h, were cultured with or without LPS for an additional 24 h. Data represent the mean ± SEM of three independent experiments (A–C). The Tukey-Kramer test (A, C) and Dunnett’s test (B) were used. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, ns, not significant.
Fig 4: βST mice have reduced IL-12p35 expression in islet myeloid cells.(A and B) Normalized cell count of classical macrophages (CD11b+CD11c–F4/80+Gr1–), hybrid macrophages (CD11b+CD11c+F4/80+Gr1–), cDC1s (CD11b–CD11c+F4/80–Gr1–), and cDC2s (CD11b+CD11c+F4/80–Gr1–) per islet (A) or per pancreatic lymph node (B) from euglycemic 14-week-old NOD βST or littermate mice. (C) Representative flow cytometry histogram of IL-12p35 expression in cDC2s from islets of euglycemic 14-week-old NOD βST and NOD littermate mice, compared with isotype control. (D) Representative flow cytometry histogram of IL-12p35 expression in hybrid macrophages from islets of euglycemic NOD βST and littermate mice, compared with isotype control. Vertical line denotes the positive gate. (E) Quantification of IL-12p35 expression shown in C and D across 7 NOD βST mice, 16 NOD littermate mice, and 5 isotype controls. Error bars represent SD. Mann-Whitney U tests were used to examine statistical differences between groups.
Fig 5: Tolerance from disease is established after 20 weeks.(A) Confirmation of ST8Sia6-myc shutoff after 5 weeks of doxycycline treatment by IHC. Schematic of doxycycline treatment for temporal control of ST8Sia6 expression. Scale bars: 100 μm. (B) Diabetes-free incidence after treatment of 15 euglycemic NOD βST and 29 euglycemic littermate mice with doxycycline starting at 8 weeks of age. (C) Comparison with disease kinetics of 8-week-old euglycemic non-doxycycline-treated NOD βST (n = 50) or littermate (n = 151) mice (subset from Figure 1C). (D) Diabetes-free incidence after treatment of 12 euglycemic NOD βST and 16 euglycemic littermate mice with doxycycline starting at 20 weeks of age. (E) Comparison with disease kinetics of 20-week-old euglycemic non-doxycycline-treated NOD βST (n = 50) or littermate (n = 115) mice (subset from Figure 1C). Log-rank Mantel-Cox test was used to analyze statistical differences in diabetes-free incidence of indicated groups. (F) Insulitis distribution in pancreas sections of NOD βST mice treated with doxycycline for 5 weeks from 8 weeks or 20 weeks of age, compared with 300-day-old pancreata from NOD βST mice never treated with doxycycline (subset from Figure 1E). Scoring and analysis as in Figure 1E. n = 69 islets from 12 mice (8-week doxycycline) or 127 islets from 11 mice (20-week doxycycline). (G and H) Ratio of T-bet+ Tregs (T-bet+FoxP3+CD4+) to Th1 T cells (T-bet+FoxP3–CD4+) (G) or to SLECs (T-bet+CD8+) (H) from islets of 20-week-old mice treated with doxycycline for greater than 5 weeks. (I) Quantification of IL-12p35 expression in hybrid macrophages (CD11b+CD11c+F4/80+Gr1–) and cDC2s (CD11b+CD11c+F4/80–Gr1–) from islets of 20-week-old mice treated with doxycycline for greater than 5 weeks. Same gating schemes as in Figures 4 and 5. Error bars represent SD. Mann-Whitney U test was used for statistical analysis between groups.
Supplier Page from BioLegend for Recombinant Mouse IL-12 (p70) (carrier-free)